Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩1,116,000.00
Day range
₩1,110,000.00 - ₩1,145,000.00
Year range
₩721,000.00 - ₩1,209,000.00
Market cap
79.93T KRW
Avg Volume
76.58K
P/E ratio
73.78
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.26T | 17.04% |
Operating expense | 334.17B | 87.16% |
Net income | 321.49B | 10.60% |
Net profit margin | 25.59 | -5.50% |
Earnings per share | 4.52K | 10.60% |
EBITDA | 476.48B | -3.14% |
Effective tax rate | 14.04% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.33T | -35.26% |
Total assets | 17.34T | 8.04% |
Total liabilities | 6.43T | 3.47% |
Total equity | 10.90T | — |
Shares outstanding | 71.17M | — |
Price to book | 7.28 | — |
Return on assets | 4.88% | — |
Return on capital | 6.80% | — |
Cash Flow
Net change in cash
| (KRW) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 321.49B | 10.60% |
Cash from operations | 389.56B | -53.23% |
Cash from investing | -1.07T | -138.92% |
Cash from financing | 514.35B | 280.15% |
Net change in cash | -149.00B | -267.89% |
Free cash flow | -30.00B | -107.16% |
About
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Founded
2011
Website
Employees
4,744
